Literature DB >> 22240480

Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells.

Maria I Almeida1, Milena S Nicoloso, Lizhi Zeng, Cristina Ivan, Riccardo Spizzo, Roberta Gafà, Lianchun Xiao, Xinna Zhang, Ivan Vannini, Francesca Fanini, Muller Fabbri, Giovanni Lanza, Rui M Reis, Patrick A Zweidler-McKay, George A Calin.   

Abstract

BACKGROUND & AIMS: MicroRNAs (miRNAs) can promote or inhibit tumor growth and are therefore being developed as targets for cancer therapies. They are diverse not only in the messenger RNAs (mRNA) they target, but in their production; the same hairpin RNA structure can generate mature products from each strand, termed 5p and 3p, that can bind different mRNAs. We analyzed the expression, functions, and mechanisms of miR-28-5p and miR-28-3p in colorectal cancer (CRC) cells.
METHODS: We measured levels of miR-28-5p and miR-28-3p expression in 108 CRC and 49 normal colorectal samples (47 paired) by reverse transcription, quantitative real-time polymerase chain reaction. The roles of miR-28 in CRC development were studied using cultured HCT116, RKO, and SW480 cells and tumor xenograft analyses in immunodeficient mice; their mRNA targets were also investigated.
RESULTS: miR-28-5p and miR-28-3p were down-regulated in CRC samples compared with normal colon samples. Overexpression of miRNAs in CRC cells had different effects and the miRNAs interacted with different mRNAs: miR-28-5p altered expression of CCND1 and HOXB3, whereas miR-28-3p bound NM23-H1. Overexpression of miR-28-5p reduced CRC cell proliferation, migration, and invasion in vitro, whereas miR-28-3p increased CRC cell migration and invasion in vitro. CRC cells overexpressing miR-28 developed tumors more slowly in mice compared with control cells, but miR-28 promoted tumor metastasis in mice.
CONCLUSION: miR-28-5p and miR-28-3p are transcribed from the same RNA hairpin and are down-regulated in CRC cells. Overexpression of each has different effects on CRC cell proliferation and migration. Such information has a direct application for the design of miRNA gene therapy trials.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240480      PMCID: PMC3321100          DOI: 10.1053/j.gastro.2011.12.047

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

Authors:  Muhua Yang; Yuan Yao; Gabriel Eades; Yongshu Zhang; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2011-06-03       Impact factor: 4.872

Review 2.  MicroRNA history: discovery, recent applications, and next frontiers.

Authors:  Maria I Almeida; Rui M Reis; George A Calin
Journal:  Mutat Res       Date:  2011-03-30       Impact factor: 2.433

Review 3.  Recently identified and potential targets for colon cancer treatment.

Authors:  Michael A Lea
Journal:  Future Oncol       Date:  2010-06       Impact factor: 3.404

4.  Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis.

Authors:  P S Steeg; G Bevilacqua; R Pozzatti; L A Liotta; M E Sobel
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

Review 5.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

6.  Identification and functional characterization of microRNAs involved in the malignant progression of gliomas.

Authors:  Bastian Malzkorn; Marietta Wolter; Franziska Liesenberg; Michael Grzendowski; Kai Stühler; Helmut E Meyer; Guido Reifenberger
Journal:  Brain Pathol       Date:  2009-09-19       Impact factor: 6.508

7.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis.

Authors:  N Arber; H Hibshoosh; S F Moss; T Sutter; Y Zhang; M Begg; S Wang; I B Weinstein; P R Holt
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

8.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.

Authors:  Ganta Vijay Chaitanya; Alexander J Steven; Phanithi Prakash Babu
Journal:  Cell Commun Signal       Date:  2010-12-22       Impact factor: 5.712

9.  Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression.

Authors:  Rajendra Kumar Palakurthy; Narendra Wajapeyee; Manas K Santra; Claude Gazin; Ling Lin; Stephane Gobeil; Michael R Green
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

10.  RDML: structured language and reporting guidelines for real-time quantitative PCR data.

Authors:  Steve Lefever; Jan Hellemans; Filip Pattyn; Daniel R Przybylski; Chris Taylor; René Geurts; Andreas Untergasser; Jo Vandesompele
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

View more
  87 in total

1.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

Review 2.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

3.  Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer.

Authors:  Martin Pichler; Cristian Rodriguez-Aguayo; Su Youn Nam; Mihnea Paul Dragomir; Recep Bayraktar; Simone Anfossi; Erik Knutsen; Cristina Ivan; Enrique Fuentes-Mattei; Sang Kil Lee; Hui Ling; Tina Catela Ivkovic; Guoliang Huang; Li Huang; Yoshinaga Okugawa; Hiroyuki Katayama; Ayumu Taguchi; Emine Bayraktar; Rajat Bhattacharya; Paola Amero; William Ruixian He; Anh M Tran; Petra Vychytilova-Faltejskova; Christiane Klec; Diana L Bonilla; Xinna Zhang; Sanja Kapitanovic; Bozo Loncar; Roberta Gafà; Zhihui Wang; Vittorio Cristini; Samir M Hanash; Menashe Bar-Eli; Giovanni Lanza; Ondrej Slaby; Ajay Goel; Isidore Rigoutsos; Gabriel Lopez-Berestein; George Adrian Calin
Journal:  Gut       Date:  2020-01-27       Impact factor: 23.059

4.  Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases.

Authors:  Janina Müller-Deile; Jan Dannenberg; Patricia Schroder; Meei-Hua Lin; Jeffrey H Miner; Rongjun Chen; Jan-Hinrich Bräsen; Thomas Thum; Jenny Nyström; Lynne Beverly Staggs; Hermann Haller; Jan Fiedler; Johan M Lorenzen; Mario Schiffer
Journal:  Kidney Int       Date:  2017-05-03       Impact factor: 10.612

5.  Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs.

Authors:  Eric Londin; Phillipe Loher; Aristeidis G Telonis; Kevin Quann; Peter Clark; Yi Jing; Eleftheria Hatzimichael; Yohei Kirino; Shozo Honda; Michelle Lally; Bharat Ramratnam; Clay E S Comstock; Karen E Knudsen; Leonard Gomella; George L Spaeth; Lisa Hark; L Jay Katz; Agnieszka Witkiewicz; Abdolmohamad Rostami; Sergio A Jimenez; Michael A Hollingsworth; Jen Jen Yeh; Chad A Shaw; Steven E McKenzie; Paul Bray; Peter T Nelson; Simona Zupo; Katrien Van Roosbroeck; Michael J Keating; George A Calin; Charles Yeo; Masaya Jimbo; Joseph Cozzitorto; Jonathan R Brody; Kathleen Delgrosso; John S Mattick; Paolo Fortina; Isidore Rigoutsos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

6.  MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Authors:  Christof Schneider; Manu Setty; Antony B Holmes; Roy L Maute; Christina S Leslie; Lara Mussolin; Angelo Rosolen; Riccardo Dalla-Favera; Katia Basso
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

7.  Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.

Authors:  Steven Klein; Hane Lee; Shahnaz Ghahremani; Pamela Kempert; Mariam Ischander; Michael A Teitell; Stanley F Nelson; Julian A Martinez-Agosto
Journal:  J Med Genet       Date:  2014-03-27       Impact factor: 6.318

8.  miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2.

Authors:  Yong-Bin Zheng; Hai-Ping Luo; Qiang Shi; Zhi-Nan Hao; Yu Ding; Qiu-Shuang Wang; Sheng-Bo Li; Gao-Chun Xiao; Shi-Lun Tong
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.

Authors:  Jared A Wallace; Ryan M O'Connell
Journal:  Blood       Date:  2017-07-27       Impact factor: 22.113

10.  Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.

Authors:  Martin Pichler; Verena Stiegelbauer; Petra Vychytilova-Faltejskova; Cristina Ivan; Hui Ling; Elke Winter; Xinna Zhang; Matthew Goblirsch; Annika Wulf-Goldenberg; Masahisa Ohtsuka; Johannes Haybaeck; Marek Svoboda; Yoshinaga Okugawa; Armin Gerger; Gerald Hoefler; Ajay Goel; Ondrej Slaby; George Adrian Calin
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.